Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
47.51
+1.22 (+2.64%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
June 26, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend
June 17, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
June 16, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
June 12, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
June 12, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
June 11, 2025
From
Bristol Myers Squibb
Via
Business Wire
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
June 11, 2025
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus
June 10, 2025
From
Philogen S.p.A.
Via
GlobeNewswire
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
June 02, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
May 28, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
May 28, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
May 22, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference
May 21, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
May 16, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
May 06, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
April 24, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
April 22, 2025
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
April 17, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
April 14, 2025
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
April 11, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
March 28, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
March 28, 2025
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
April 08, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
March 14, 2025
From
Bristol Myers Squibb
Via
Business Wire
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
March 27, 2025
EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025
March 13, 2025
From
Bristol Myers Squibb
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
March 11, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
March 08, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
March 07, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend
March 03, 2025
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.